The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention - Abstract

Office of Oncology Drug Products, Office of New Drugs, and the Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

 

The use of 5α-reductase inhibitors for prevention of prostate cancer continues to be widely discussed within the scientific and medical communities.(1) Much of this discussion has been fueled by the findings of two large randomized, placebo-controlled trials - the Prostate Cancer Prevention Trial (PCPT) with finasteride and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial (ClinicalTrials.gov number, NCT00056407).(2),(3) Together, these trials showed an overall relative reduction of 23 to 25% in prostate-cancer diagnoses, a seemingly significant benefit from drugs aimed at preventing one of the most common cancers in men. However, the observed reduction resulted from a . . .

Written by:
Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R.   Are you the author?

Reference: N Engl J Med. 2011 Jun 15. Epub ahead of print.
doi: 10.1056/NEJMp1106783

PubMed Abstract
PMID: 21675880

UroToday.com Prostate Cancer Section

 

 

email news signup